Equity-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2025

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Schedule of stock option activity

	OPTIONS			WEIGHTED- AVERAGE EXERCISE PRICE		WEIGHTED- AVERAGE REMAINING CONTRACTUAL TERM (IN YEARS)		AGGREGATE INTRINSIC VALUE (IN THOUSANDS)
Outstanding as of December 31, 2024		5,155,414		$	35.12		9.4	$	61,506
Granted		275,540		$	37.76		—	$	—
Exercised		(28,799	)	$	21.61		—	$	—
Forfeited		(46,166	)	$	28.93		—	$	—
Outstanding as of March 31, 2025		5,355,989		$	35.38		9.2	$	39,345
Exercisable as of March 31, 2025		962,645		$	25.55		8.8	$	12,870

Schedule of restricted stock unit activity

	NUMBER OF SHARES			WEIGHTED- AVERAGE GRANT DATE FAIR VALUE PER SHARE
Unvested restricted stock units as of December 31, 2024		267,564		$	38.48
Vested		(18,646	)	$	36.56
Forfeited		(3,674	)	$	40.30
Unvested restricted stock units as of March 31, 2025		245,244		$	38.60

Schedule of equity-based compensation expense

	THREE MONTHS ENDED MARCH 31,
	2025		2024
Research and development expense	$	5,372	$	1,930
General and administrative expense		5,754		2,256
Total	$	11,126	$	4,186

Unvested restricted common stock

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Schedule of activity of equity instrument other than option

	NUMBER OF SHARES			WEIGHTED- AVERAGE GRANT DATE FAIR VALUE PER SHARE
Unvested restricted common stock as of December 31, 2024		1,415,827		$	5.30
Vested		(194,458	)	$	4.98
Unvested restricted common stock as of March 31, 2025		1,221,369		$	5.36

2023 Equity Incentive Plan | Employee Stock Option

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Schedule of fair value assumptions of share based payment

	THREE MONTHS ENDED MARCH 31,
	2025
Risk-free interest rate	4.0% - 4.4%
Expected dividend yield	0.0%
Expected term (in years)	6.0 - 6.25
Expected volatility	74.8% - 75.2%